Ligand Pharmaceuticals and Pfizer have sublicensed Tanaproget, also known as NSP-989, to a multi-national pharmaceutical company. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer, as well as royalties on sales. Tanaproget is a tissue-selective, non-steroidal contraceptive progesterone receptor agonist that has the potential for an improved side effect profile over current steroid-contain...